Opportunities and challenges in combination gene cancer therapy

Nastiuk, Kent L.; Krolewski, John J.

doi:10.1016/j.addr.2015.12.005

Cited by 85Virus-based gene therapy researchRNA Interference and Gene DeliveryCancer Research and Treatments

Opportunities and challenges in combination gene cancer therapy

Open access

Nastiuk, Kent L., Krolewski, John J.·2016·Advanced Drug Delivery Reviews

DOI 10.1016/j.addr.2015.12.005PMC PMC4957561

Open this paper in CoChat — free account

Abstract

Treatment for solid tumor malignancies, which constitute the majority of human cancers, is still dominated by surgery and radiotherapies. This is especially true for many localized solid tumors, which are often curable with these treatments. However, metastatic cancers are beyond the reach of these therapies, and many localized cancers that are initially treated with surgery and radiation will recur and metastasize. Thus, for over 60years there has been a concerted effort to develop effective drug treatments for metastatic cancers. Combination therapies are an increasingly important part of the anti-cancer drug armamentarium. In the case of cytotoxic chemotherapy, multi-drug regimens rapidly became the norm, as the earliest single agents were relatively ineffective. In contrast to chemotherapy, where combination therapies were required in order to achieve treatment efficacy, for both hormonal and targeted therapies the impetus to move toward the use of combination therapies is to prevent or reverse the development of treatment resistance. In addition, emerging evidence suggests that combination therapy may also improve cancer treatment by neutralizing an emerging treatment side effect termed therapy-induced metastasis, which accompanies some effective single agent therapies. Finally, although gene therapy is still far from use in the clinic, we propose that combination therapies may enhance its effectiveness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.addr.2015.12.005

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Smart nanoparticles build up in the tumor by using the EPR effect or receptor-mediated extravasation, bind to tumor receptors, enter cancer cells by endocytosis, and release medications there.
“By using the ERP effect or receptor-mediated extravasation, the smart nanoparticles build up in the tumor, bind to tumor receptors, enter cancer cells by endocytosis, and release medications there.336”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [336]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Cancer statistics, 2009
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709 · see citing works
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · see citing works
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · see citing works
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · see citing works
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works
Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856 · see citing works
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028 · see citing works
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 1× · see citing works
“Problems with pre-clinical trial reproducibility may be a cause of the low rate of drug development success [75,76], but it could also be that murine models, even those genetically engineered to resemble human cancers, are not adequate models, and therefore restoration of a single tumor suppressor gene is simply not s…”
Background
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,908 · see citing works
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · see citing works
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710 · see citing works
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · see citing works
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,198 · see citing works
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,973 · see citing works
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,753 · see citing works
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · see citing works
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Fizazi, K. S., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S. A., Vogelzang, N. J., Fred Saad, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,376 · see citing works
TNF-α Induces Two Distinct Caspase-8 Activation Pathways
Wang, L., Du, F., & Wang, X. (2008) · Cell · doi:10.1016/j.cell.2008.03.036 · Cited by 1,352 · see citing works
Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Huggins, C. E., & Hodges, C. V. (1972) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.22.4.232 · Cited by 1,322 · see citing works
Policy: NIH plans to enhance reproducibility
Collins, F. S., & Tabak, L. A. (2014) · Nature · doi:10.1038/505612a · Cited by 1,247 · see citing works
Targeted cancer therapy
Sawyers, C. L. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,171 · see citing works
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · see citing works
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M., Efstathiou, E., Rathkopf, D. E., Shelkey, J., Yu, E. Y., Alumkal, J. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063 · see citing works
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 950 · see citing works
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M. P., Yang, R., Escara-Wilke, J. F., Wilder-Romans, K., Dhanireddy, S., Engelke, C. G., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 923 · see citing works
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866 · see citing works
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747 · see citing works
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 717 · see citing works
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
Miyamoto, D. T., Zheng, Y., Wittner, B. S., Lee, R. J., Zhu, H., Broderick, K. T., Desai, R. N., Fox, D. B., Brannigan, B. W., Trautwein, J., et al. (2015) · Science · doi:10.1126/science.aab0917 · Cited by 706 · see citing works
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S. P., Matsumoto, A. M., Nelson, P. S., & Montgomery, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 583 · see citing works
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B. D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578 · see citing works
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Korpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0142 · Cited by 559 · see citing works
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Boettcher, M., & McManus, M. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.028 · Cited by 510 · see citing works
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.81 · Cited by 455 · see citing works
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 444 · see citing works
The Emperor of All Maladies: A Biography of Cancer
Mukherjee, S. (2010) · Cited by 416 · see citing works
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
Pienta, K. J., Machiels, J.-P., Schrijvers, D. L. A. L., Alekseev, B. Y., Shkolnik, M. I., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C. H. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 413 · see citing works
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397 · see citing works
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2013) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 367 · see citing works
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M. Y., Cortes, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.006 · Cited by 363 · see citing works
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations
Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0326 · Cited by 362 · see citing works
Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo
Loberg, R. D., Chi, Y., Craig, M., Day, L. L., Sargent, E., Neeley, C. K., Wojno, K. J., Snyder, L. A., Li, Y., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333 · see citing works
Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study
Spriggs, D. R., Sherman, M. L., MICHIE, H. R., Arthur, K. A., Imamura, K., Wilmore, D. W., Frei, E., & Kufe, D. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.13.1039 · Cited by 309 · see citing works
Pushing the limits of targeted therapy in chronic myeloid leukaemia
O’Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3317 · Cited by 302 · see citing works
A tragic setback
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 291 · see citing works
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Sandhu, S. K., Papadopoulos, K. P., Fong, P. C. C., Patnaik, A., Messiou, C., Olmos, D., Wang, G., Tromp, B. J., Puchalski, T. A., Balkwill, F. R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2099-8 · Cited by 273 · see citing works
Releasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 256 · see citing works
Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2‐induced STAT3 activation
Izumi, K., Fang, L., Mizokami, A., Namiki, M., Li, L., Lin, W., & Chang, C. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202367 · Cited by 247 · see citing works
CCL2 as an Important Mediator of Prostate Cancer Growth In Vivo through the Regulation of Macrophage Infiltration
Loberg, R. D., Chi, Y., Craig, M., Li, Y., Snyder, L. A., & Pienta, K. J. (2007) · Neoplasia · doi:10.1593/neo.07307 · Cited by 242 · see citing works
Furin‐Mediated Sequential Delivery of Anticancer Cytokine and Small‐Molecule Drug Shuttled by Graphene
Jiang, T., Sun, W., Zhu, Q., Burns, N. A., Khan, S. A., Mo, R., & Gu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201404498 · Cited by 228 · see citing works
Therapeutic targeting of tumor suppressor genes
Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 201 · see citing works
Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
Yu, Z., Chen, S., Sowalsky, A. G., Voznesensky, O. S., Mostaghel, E. A., Nelson, P. S., Cai, C., & Balk, S. P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1863 · Cited by 194 · see citing works
A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways
Morton, S. W., Lee, M. J., Deng, Z. J., Dreaden, E. C., Siouve, E., Shopsowitz, K. E., Shah, N. J., Yaffe, M. B., & Hammond, P. T. (2014) · Science Signaling · doi:10.1126/scisignal.2005261 · Cited by 190 · see citing works
Second Child in French Trial Is Found to Have Leukemia
Marshall, E. (2003) · Science · doi:10.1126/science.299.5605.320 · Cited by 170 · see citing works
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
Lin, T., Izumi, K., Lee, S. O., Lin, W.-J., Yeh, S.-D., & Chang, C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.270 · Cited by 166 · see citing works
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 163 · see citing works
IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins
Conticello, C., Pedini, F., Zeuner, A., Patti, M., Zerilli, M., Stassi, G., Messina, A., Peschle, C., & Maria, R. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5467 · Cited by 161 · see citing works
Adaptation or selection—mechanisms of castration-resistant prostate cancer
Zong, Y., & Goldstein, A. S. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.237 · Cited by 133 · see citing works
Smac mimetics and innate immune stimuli synergize to promote tumor death
Beug, S. T., Tang, V. A., LaCasse, E. C., Cheung, H. H., Beauregard, C. E., Brun, J., Nuyens, J. P., Earl, N., St-Jean, M., Holbrook, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2806 · Cited by 132 · see citing works
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
Eiring, A. M., Page, B. D. G., Kraft, I. L., Mason, C. C., Vellore, N. A., Resetca, D., Zabriskie, M. S., Zhang, T. Y., Khorashad, J. S., Engar, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.245 · Cited by 132 · see citing works
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation
Spratt, D. E., Evans, M. J., Davis, B. J., Doran, M. G., Lee, M. X., Shah, N., Wongvipat, J., Carnazza, K. E., Klee, G. G., Polkinghorn, W. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0892 · Cited by 127 · see citing works
Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9® Lead to Promotion versus Suppression of Prostate Cancer Metastasis
Lin, T., Lee, S. O., Niu, Y., Xu, D., Liang, L., Li, L., Yeh, S. D., Fujimoto, N., Yeh, S., & Chang, C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.477216 · Cited by 120 · see citing works
The Ins and Outs of Bcr-Abl Inhibition
Reddy, E. P., & Aggarwal, A. K. (2012) · Genes & Cancer · doi:10.1177/1947601912462126 · Cited by 120 · see citing works
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Tucci, M., Bertaglia, V., Vignani, F., Buttigliero, C., Fiori, C., Porpiglia, F., Scagliotti, G. V., & Maïo, M. D. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.013 · Cited by 119 · see citing works
Approval Summary
Dagher, R. N., Li, N., Abraham, S., Rahman, A., Sridhara, R., & Pazdur, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1402 · Cited by 88 · see citing works
Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival
Sharma, J., Gray, K. P., Harshman, L. C., Evan, C. P., Nakabayashi, M., Fichorova, R. N., Rider, J. R., Mucci, L. A., Kantoff, P. W., & Sweeney, C. J. (2014) · The Prostate · doi:10.1002/pros.22788 · Cited by 85 · see citing works
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 83 · see citing works
From pathogenesis to prevention of castration resistant prostate cancer
Bonkhoff, H., & Berges, R. R. (2009) · The Prostate · doi:10.1002/pros.21042 · Cited by 78 · see citing works
FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells
Cornforth, A. N., Davis, J. S., Khanifar, E., Nastiuk, K. L., & Krolewski, J. J. (2008) · Oncogene · doi:10.1038/onc.2008.80 · Cited by 77 · see citing works
Self-citation
The Androgen Receptor Directly Targets the Cellular Fas/FasL-Associated Death Domain Protein-Like Inhibitory Protein Gene to Promote the Androgen-Independent Growth of Prostate Cancer Cells
Gao, S., Lee, P., Wang, H., Gerald, W. L., Adler, M., Zhang, L., Wang, Y., & Wang, Z. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0445 · Cited by 75 · see citing works
Use of nanoscale delivery systems to maintain synergistic drug ratiosin vivo
Dicko, A., Mayer, L. D., & Tardi, P. G. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.538678 · Cited by 75 · see citing works
Down-regulation of c-FLIP Enhances Death of Cancer Cells by Smac Mimetic Compound
Cheung, H. H., Mahoney, D. J., LaCasse, E. C., & Korneluk, R. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1794 · Cited by 75 · see citing works
Gene Therapy Used in Cancer Treatment
Wirth, T. C., & Ylä‐Herttuala, S. (2014) · Biomedicines · doi:10.3390/biomedicines2020149 · Cited by 67 · see citing works
Identification of Small Molecules that Sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors
Schimmer, A. D., Thomas, M. P., Hurren, R., Gronda, M., Pellecchia, M., Pond, G. R., Konopleva, M. Y., Gurfinkel, D., Mawji, I. A., Brown, E. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1061 · Cited by 67 · see citing works
Overview of the latest treatments for castration-resistant prostate cancer
Bishr, M., & Fred Saad, C. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.137 · Cited by 66 · see citing works
Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies
Bartsch, H. H., Pfizenmaier, K., Schroeder, M. P., & Nagel, G. A. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90021-7 · Cited by 64 · see citing works
Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland
Gao, S., Wang, H., Lee, P., Melamed, J., Li, C. X., Zhang, F., Wu, H., Zhou, L., & Wang, Z. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01991 · Cited by 61 · see citing works
Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis
Ebos, J. M. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0308 · Cited by 59 · see citing works
Involvement of FLIP in 2-Methoxyestradiol–Induced Tumor Regression in Transgenic Adenocarcinoma of Mouse Prostate Model
Ganapathy, M., Ghosh, R., Jianping, X., Zhang, X., Bedolla, R. G., Schoolfield, J. D., Yeh, I., Troyer, D. A., Olumi, A. F., & Kumar, A. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1389 · Cited by 39 · see citing works
TNF Is Necessary for Castration-Induced Prostate Regression, Whereas TRAIL and FasL Are Dispensable
Davis, J. S., Nastiuk, K. L., & Krolewski, J. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0312 · Cited by 31 · see citing works
Self-citation
Androgen regulation of FLICE‐like inhibitory protein gene expression in the rat prostate
Nastiuk, K. L., Kim, J. W., Mann, M., & Krolewski, J. J. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10283 · Cited by 28 · see citing works
Self-citation
TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures
Sha, K., Yeh, S., Chang, C., Nastiuk, K. L., & Krolewski, J. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4535 · Cited by 28 · see citing works
Self-citation
Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL‐mediated apoptosis
Raclaw, K. A., Heemers, H. V., Kidd, E., Dehm, S. M., & Tindall, D. J. (2008) · The Prostate · doi:10.1002/pros.20844 · Cited by 24 · see citing works
Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers
Awad, M. M., & Hammerman, P. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4172 · Cited by 20 · see citing works
FLICE-Like Inhibitory Protein Blocks Transforming Growth Factor β1–Induced Caspase Activation and Apoptosis in Prostate Epithelial Cells
Nastiuk, K. L., Yoo, K., Lo, K., Su, K. W., Yeung, P., Kutaka, J., Danielpour, D., & Krolewski, J. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0386 · Cited by 13 · see citing works
Self-citation
Transforming growth factor ß1 induces apoptosis by suppressing FLICE‐like inhibitory protein in DU145 prostate epithelial cells
Yoo, K. S., Nastiuk, K. L., & Krolewski, J. J. (2008) · International Journal of Cancer · doi:10.1002/ijc.24024 · Cited by 11 · see citing works
Self-citation
'Financial toxicity' looms as cancer combinations proliferate
Morrison, C. (2015) · Nature Biotechnology · doi:10.1038/nbt0815-783 · Cited by 10 · see citing works
Approval may embolden industry to combine cancer therapies
Deng, B. (2015) · Nature Medicine · doi:10.1038/nm0215-105 · Cited by 7 · see citing works
Untitled work
(2002) · doi:10.1002/1439-7633(20021004)3:10

Flagged first, then by citations

1 of the 99 references couldn’t be matched to a known paper.

Sorted by citations

Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works
Chitosan Derivatives and Their Application in Biomedicine
Wang, W., Meng, Q., Li, Q., Liu, J., Zhou, M., Jin, Z., & Zhao, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020487 · Cited by 991 · see citing works
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406 · see citing works
RNA interference-based therapy and its delivery systems
Chen, X., Mangala, L. S., Rodriguez‐Aguayo, C., Kong, X., Lopez‐Berestein, G., & Sood, A. K. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9717-6 · Cited by 333 · see citing works
A DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy
Liu, J., Song, L., Liu, S., Jiang, Q., Liu, Q. L., Li, N., Wang, Z., & Ding, B. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b04812 · Cited by 269 · see citing works
Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy
Qi, S., Sun, J.-H., Yu, H.-H., & Yu, S. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1410256 · Cited by 219 · see citing works
Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges
Zhang, M., Zang, X., Wang, M., Li, Z., Qiao, M., Hu, H., & Chen, D. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00170k · Cited by 210 · see citing works
Nanomaterial-Enabled Cancer Therapy
Quader, S., & Kataoka, K. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.026 · Cited by 156 · see citing works
Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy
Kim, H., Jang, H., Cho, H., Choi, J., Hwang, K. Y., Choi, Y., Kim, S. H., & Yang, Y. (2021) · Cancers · doi:10.3390/cancers13174435 · Cited by 152 · see citing works
Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy
Liu, Q., Wang, C., Zheng, Y., Zhao, Y., Wang, Y., Hao, J., Zhao, X., Yi, K., Shi, L., Kang, C., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120275 · Cited by 145 · see citing works
Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy
Bostami, R. D. A., Abuwatfa, W. H., & Husseini, G. A. (2022) · Nanomaterials · doi:10.3390/nano12152672 · Cited by 121 · see citing works
Non-coding RNAs as potential therapeutic targets in breast cancer
Tomar, D., Yadav, A. S., Kumar, D., Bhadauriya, G., & Kundu, G. C. (2019) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.04.005 · Cited by 81 · see citing works
siRNA-loaded poly(histidine-arginine)6-modified chitosan nanoparticle with enhanced cell-penetrating and endosomal escape capacities for suppressing breast tumor metastasis
Sun, P., Huang, W., Kang, L., Jin, M., Fan, B., Jin, H., Wang, Q., & Gao, Z. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s129436 · Cited by 64 · see citing works
Retracted
Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress
Sun, Z., Huang, J., Fishelson, Z., Wang, C., & Zhang, S. (2023) · Biomedicines · doi:10.3390/biomedicines11071971 · Cited by 63 · see citing works
Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review
Zhang, J., Zhang, T., & Gao, J. (2022) · Nanomaterials · doi:10.3390/nano12193323 · Cited by 62 · see citing works
Mesoporous Silica Nanoparticles as a Gene Delivery Platform for Cancer Therapy
Khaliq, N. U., Lee, J., Kim, J., Kim, Y., Yu, S., Kim, J. S., Kim, S., Sung, D., & Kim, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051432 · Cited by 56 · see citing works
Programmable DNA Nanoflowers for Biosensing, Bioimaging, and Therapeutics
Lv, J., Dong, Y., Gu, Z., & Yang, D. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002242 · Cited by 55 · see citing works
Elevating Second Near-Infrared Photothermal Conversion Efficiency of Hollow Gold Nanorod for a Precise Theranostic of Orthotopic Bladder Cancer
Zhang, W., Cai, K., Sun, Z., Xiang, Q., Li, Y., Fu, M., Liu, X., Foda, M. F., Ye, Z., Huang, J., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04175 · Cited by 49 · see citing works
Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy
Wu, M., Liu, X., Jin, W., Li, Y., Li, Y., Hu, Q., Chu, P. K.-H., Tang, G., & Yuan, P. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.011 · Cited by 48 · see citing works
A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation
Gutiérrez, D. A., DeJesus, R. E., Contreras, L., Rodriguez‐Palomares, I. A., Villanueva, P. J., Balderrama, K. S., Monterroza, L., Larragoity, M., Varela-Ramı́rez, A., & Aguilera, R. J. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09466-8 · Cited by 44 · see citing works
Fabrication of PEGylated Fe@Bi 2 S 3 nanocomposites for dual-mode imaging and synergistic thermoradiotherapy
Li, E., Cheng, X., Deng, Y., Zhu, J., Xu, X., Saw, P. E., Gu, H., Ge, C., & Pan, Y. (2018) · Biomaterials Science · doi:10.1039/c8bm00336j · Cited by 42 · see citing works
Progress in nonviral gene therapy for breast cancer and what comes next?
Bottai, G., Truffi, M., Corsi, F., & Santarpia, L. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1305351 · Cited by 40 · see citing works
Bio-nanomaterials: Promising anticancer properties and treatment strategies
Elemike, E. E., Onunkwo, I. C., Ughumiakpor, O., Alawuru, F., Mukoro, A., Ishom, P., Obarakpor, F., Hossain, I., & Aziza, A. E. (2025) · Nano TransMed · doi:10.1016/j.ntm.2025.100076 · Cited by 41 · see citing works
Multifunctional Double-Bundle DNA Tetrahedron for Efficient Regulation of Gene Expression
Wu, T., Liu, Q. L., Cao, Y., Tian, R., Liu, J., & Ding, B. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c08886 · Cited by 38 · see citing works
Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy
Huang, F., Dai, C., Zhang, Y.-N., Zhao, Y., Wang, Y., & Ru, G. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.889403 · Cited by 37 · see citing works
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants
Aboulkassim, T., Tian, X., Liu, Q., Qiu, D., Hancock, M. A., Wu, J. H., & Batist, G. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113104 · Cited by 35 · see citing works
Deeply Infiltrating iRGD‐Graphene Oxide for the Intensive Treatment of Metastatic Tumors through PTT‐Mediated Chemosensitization and Strengthened Integrin Targeting‐Based Antimigration
Wang, H., Zhou, J., Fu, Y., Zheng, Y., Shen, W., Zhou, J., & Yin, T. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100536 · Cited by 35 · see citing works
Emerging trends and research foci of berberine on tumor from 2002 to 2021: A bibliometric article of the literature from WoSCC
Yuan, R., Tan, Y., Sun, P., Qin, B., & Liang, Z. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1122890 · Cited by 34 · see citing works
Precise synchronization of hyperthermia–chemotherapy: photothermally induced on-demand release from injectable hydrogels of gold nanocages
Wan, J., Geng, S., Zhao, H., Peng, X., Xu, J., Wei, M., Mao, J., Zhou, Y., Zhu, Q. G., Zhao, Y., et al. (2018) · Nanoscale · doi:10.1039/c8nr06851h · Cited by 34 · see citing works
Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules
Yuan, P., Yang, F., Liew, S. S., Yan, J., Dong, X., Wang, J., Du, S., Mao, X., Gao, L., & Yao, S. Q. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121376 · Cited by 34 · see citing works
Recent development of gene therapy for pancreatic cancer using non-viral nanovectors
Liu, Y., Wu, W., Wang, Y., Han, S., Yuan, Y., Huang, J., Shuai, X., & Peng, Z. M. (2021) · Biomaterials Science · doi:10.1039/d1bm00748c · Cited by 33 · see citing works
Multiple roles and regulatory mechanisms of the transcription factor GATA6 in human cancers
Sun, Z., & Yan, B. (2019) · Clinical Genetics · doi:10.1111/cge.13630 · Cited by 31 · see citing works
Nanodevices for the Efficient Codelivery of CRISPR-Cas9 Editing Machinery and an Entrapped Cargo: A Proposal for Dual Anti-Inflammatory Therapy
García‐Fernández, A., Vivo‐Llorca, G., Sancho, M., García-Jareño, A. B., Ramírez‐Jiménez, L., Barber‐Cano, E., Murguía, J. R., Orzáez, M., Sancenón, F., & Martínez‐Máñez, R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071495 · Cited by 30 · see citing works
Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
Lin, X., Peng, Z., Wang, X., Zou, J., Chen, D., Chen, Z., Li, Z., Dong, B., Gao, J., & Shen, L. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1314-x · Cited by 29 · see citing works
tLyp-1-conjugated GSH-sensitive biodegradable micelles mediate enhanced pUNO1-hTRAILa/curcumin co-delivery to gliomas
Xiang, Y., Duan, X., Feng, L., Jiang, S., Deng, L., Shen, J., Yang, Y., & Guo, R. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.05.186 · Cited by 27 · see citing works
Fusion of Exosomes and Nanotechnology: Cutting-Edge Cancer Theranostics
Agnihotram, R., Dhar, R., Dhar, D., Purushothaman, K., Narasimhan, A. K., & Devi, A. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c01033 · Cited by 26 · see citing works
Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones
Contreras, L., Calderon, R. I., Varela-Ramı́rez, A., Zhang, H., Quan, Y., Das, U., Dimmock, J. R., Skouta, R., & Aguilera, R. J. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0397-1 · Cited by 24 · see citing works
Co-delivery systems: hope for clinical application?
Nezhadi, S., & Dorkoosh, F. A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01041-1 · Cited by 24 · see citing works
Layer‐by‐Layer Assembly of Functional Nanoparticles for Hepatocellular Carcinoma Therapy
Gao, X., He, Z., Ni, W., Jian, X., Hu, C., Zhao, Y., Yan, Y., & Wei, X. C. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201904246 · Cited by 24 · see citing works
Hyaluronan-Stabilized Redox-Sensitive Nanoassembly for Chemo-Gene Therapy and Dual T1/T2 MR Imaging in Drug-Resistant Breast Cancer Cells
Rajendrakumar, S. K., Venu, A., Revuri, V., Thomas, R. G., Thirunavukkarasu, G. K., Zhang, J., Vijayan, V., Choi, S., Lee, J. Y., Lee, Y.-K., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00189 · Cited by 23 · see citing works
Preclinical and First-in-Human Study of a Compact Radionuclide Labeled Self-Assembly Nanomedicine for Chemo-Radio-Theranostics of Cancer
Xiong, H., Wang, R., Zhang, H., Zhang, Q., Qin, Y., Du, C., Zhang, X., Ye, J., Shi, C., Shen, H., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c18489 · Cited by 22 · see citing works
Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
Li, Y., Guo, W., Li, X., Zhang, J., Sun, M., Tang, Z., Ran, W., Yang, K., Huang, G., & Li, L. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00145-1 · Cited by 22 · see citing works
Exosomes as Novel Delivery Systems for Application in Traditional Chinese Medicine
Chen, Q., Wu, D., Wang, Y., & Chen, Z. (2022) · Molecules · doi:10.3390/molecules27227789 · Cited by 20 · see citing works
Multifunctionalized polyethyleneimine-based nanocarriers for gene and chemotherapeutic drug combination therapy through one-step assembly strategy
Jiang, D., Wang, M., Wang, T., Zhang, B., Liu, C., & Zhang, N. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s142966 · Cited by 18 · see citing works
Prospects of Gene Therapy to Treat Melanoma
Menezes, M. E., Talukdar, S., Wechman, S. L., Das, S. K., Emdad, L., Sarkar, D., & Fisher, P. B. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.007 · Cited by 18 · see citing works
Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer
Hurtado, M., Sankpal, U. T., Ranjan, A. P., Maram, R., Vishwanatha, J. K., Nagaraju, G. P., El‐Rayes, B. F., & Basha, R. M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.016 · Cited by 17 · see citing works
Decoding contextual crosstalk: revealing distinct interactions between non-coding RNAs and unfolded protein response in breast cancer
Karamali, N., Daraei, A., Rostamlou, A., Mahdavi, R., Jonoush, Z. A., Ghadiri, N., Mahmoudi, Z., Mardi, A., Javidan, M., Sohrabi, S., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03296-3 · Cited by 18 · see citing works
Antitumor Research Based on Drug Delivery Carriers: Reversing the Polarization of Tumor-Associated Macrophages
Cao, X., Wan, S., Wu, B., Liu, Z., Xu, L., Ding, Y. J., & Huang, H. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01277 · Cited by 15 · see citing works
Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives
Zhou, Y., Zhang, Q., Zhao, Z., Hu, X., You, Q., & Jiang, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116270 · Cited by 14 · see citing works
Polymeric micelles self-assembled from amphiphilic polymers with twin disulfides used as siRNA carriers to enhance the transfection
Zhang, C. Y., Peng, S., Zhao, B., Luo, W., & Zhang, L. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.04.039 · Cited by 15 · see citing works
Potential Therapeutic Efficacy of Ferulic Acid and Its Derivatives in the Management of Cancers: A Comprehensive Analysis With Mechanistic Insight
Ahmmed, S., Bhuia, M. S., Chowdhury, R., Munshi, M. H., Eity, T. A., Kamli, H. M., & Islam, M. T. (2025) · International Journal of Food Science · doi:10.1155/ijfo/2256871 · Cited by 14 · see citing works
Tumour targeted polymer nanoparticles co-loaded with docetaxel and siCCAT2 for combination therapy of lung cancer
Xiao, D., Hu, X., & Zhang, J. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.2016773 · Cited by 14 · see citing works
Natural macromolecules polysaccharide-based drug delivery systems targeting tumor necrosis factor alpha receptor for the treatment of cancer: A review
Raza, M. A., Khatoon, N., Parveen, R., Nirisha, V., Thakur, Y., Thakur, Y., Lata, K. A., Shifana, A. S., Disouza, J., Saoji, S. D., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145145 · Cited by 13 · see citing works
Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery
Berman, M., Mattheolabakis, G., Suresh, M., & Amiji, M. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1178236 · Cited by 12 · see citing works
Dextranated poly(urethane amine)s designed for systemic gene delivery in ovarian cancer therapy
Zhao, J., Han, F., Zhao, P., Wen, X., & Lin, C. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01641g · Cited by 12 · see citing works
DNA/RNA-based formulations for treatment of breast cancer
Xie, Z., & Zeng, X. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1317744 · Cited by 12 · see citing works
“Layer peeling” co-delivery system for enhanced RNA interference-based tumor associated macrophages-specific chemoimmunotherapy
Wang, T., Mu, W., Li, F., Zhang, J., Hou, T., Pang, X., Yin, X., & Zhang, N. (2020) · Nanoscale · doi:10.1039/d0nr04025h · Cited by 12 · see citing works
Multifaceted behavior of PEST sequence enriched nuclear proteins in cancer biology and role in gene therapy
Sarfraz, M., Afzal, A., Khattak, S., Saddozai, U. A. K., Li, H., Zhang, Q., Madni, A., Haleem, K. S., Duan, S., Wu, D., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30011 · Cited by 12 · see citing works
Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update
Moaveni, A. K., Amiri, M., Shademan, B., Farhadi, A., Behroozi, J., & Nourazarian, A. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1382190 · Cited by 11 · see citing works
Exploring combinations of dihydroartemisinin for cancer therapy: A comprehensive review
Rani, K., Sahu, R. C., Chaudhuri, A., Kumar, D. N., Arora, S., Kumari, V., & Agrawal, A. K. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151854 · Cited by 11 · see citing works
Multiple roles of mothers against decapentaplegic homolog 4 in tumorigenesis, stem cells, drug resistance, and cancer therapy
Dai, C., Cao, Y., Huang, F., & Wang, Y. (2022) · World Journal of Stem Cells · doi:10.4252/wjsc.v14.i1.41 · Cited by 9 · see citing works
NK-derived exosomes in anti-tumor strategies
Zhang, A., Yin, X., & Ma, J. (2025) · Medical Oncology · doi:10.1007/s12032-025-02965-1 · Cited by 8 · see citing works
Development of a nontoxic and efficient gene delivery vector based on histidine grafted chitosan
Liu, T., Lin, M., Wu, F., Lin, A., Luo, D., & Zhang, Z. (2021) · International Journal of Polymeric Materials · doi:10.1080/00914037.2021.1885407 · Cited by 8 · see citing works
Controlling Release Kinetics of an Adjuvant from a Depot Improves the Efficacy of Local Immunotherapy in Metastatic Cancer
Milligan, J. J., Strader, R. L., Chakrabarty, A., Ney, M. R., Sirohi, P., Su, J. C., Varanko, A. K., Shmidov, Y., Tsolova, K. N., Fontes, C. M., et al. (2025) · Advanced Science · doi:10.1002/advs.202503591 · Cited by 7 · see citing works
Lipid-Based Nanoparticles for Targeted Drug Delivery of Anticancer Drug
Shegokar, R., Athawale, R., Kurup, N., Yang, R., & Chougule, M. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809717-5.00011-7 · Cited by 6 · see citing works
Functionalized magnetic nanoparticles for cancer therapy
Sabzini, M., Moradi, A., Sahrayi, H., Shamsabadipour, A., Namazifard, S., Hojjati, S., & Mostafavi, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00025-2 · Cited by 5 · see citing works
Extracellular Nanovesicle Enhanced Gene Transfection Using Polyethyleneimine in HEK293T Cells and Zebrafish Embryos
Zhang, Z., Wen, K., Zhang, C., Laroche, F., Wang, Z., Zhou, Q., Liu, Z., Abrahams, J. P., & Zhou, X. Y. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00448 · Cited by 5 · see citing works
Inhibition of glycolysis represses the growth and alleviates the endoplasmic reticulum stress of breast cancer cells by regulating TMTC3
Hu, X., Guo, B., Sun, T., & Wang, W. (2023) · Open Medicine · doi:10.1515/med-2023-0635 · Cited by 5 · see citing works
Emerging roles of mesoporous silica nanoparticles in personalized medicine: revolutionizing therapy and diagnosis — a comprehensive review
Gharehbaba, A. M., Soltanmohammadi, F., Eskandani, M., & Adibkia, K. (2026) · Results in Engineering · doi:10.1016/j.rineng.2026.110396 · Cited by 4 · see citing works
A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials
Patera, A. C., Maidment, J., Maroj, B., Mohamed, A. R., & Twomey, K. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00465-z · Cited by 4 · see citing works
Strongly preserved modules between cancer tissue and cell line contribute to drug resistance analysis across multiple cancer types
Dong, S., Song, C., Qi, B., Jiang, X., Liu, L., & Xu, Y. (2021) · Genomics · doi:10.1016/j.ygeno.2021.02.015 · Cited by 4 · see citing works
Auranofin Combination Therapy: A New Frontier in Cancer Treatment
Guzman-Gomez, D. L., Telukutla, S. R., Ojha, R., Bhargava, S. K., & Plebanski, M. (2026) · Molecules · doi:10.3390/molecules31030571 · Cited by 3 · see citing works
Advances in targeted protein degradation for cancer immunotherapy
Sun, Y., Li, M., Zou, Y., & Shi, B. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100403 · Cited by 3 · see citing works
Determination of the anti-polo like kinase 1 potential of novel derivatives of thiophene using oncoinformatics approach
Aljbreen, M. K., Alrashidi, M. M., Abouzied, A. S., Shaikh, S., & Rizvi, S. M. D. (2022) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v20i3.9 · Cited by 3 · see citing works
Expressions of some antioxidant genes in SH-SY5Y cells treated with β-lapachone, morphine and electromagnetic field
Mahmoudinasab, H., & Saadat, M. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4172-1 · Cited by 3 · see citing works
Inhibition of LONP1 in prostate cancer: bibliometrics-guided target screening and AI-driven antibody design
Pan, J., Zhang, Y., Yang, A., JIANG, L., Shen, Y., Sun, Y., Zhu, J., Chen, Z., Fan, M., & Shi, J. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004705 · Cited by 2 · see citing works
Computational Intelligence in Drug Discovery for Non-small Cell Lung Cancer
Bilal, E. S., Mahmud, M., & Ball, G. (2022) · Brain informatics and health · doi:10.1007/978-981-19-5272-2_3 · Cited by 2 · see citing works
One Novel BiP/GRP78 Inhibitor YUM70 Induces GSDME Dependent Pyroptosis and Enhances Sensitivity To EGFR Inhibitors in cholangiocarcinoma and hepatocellular carcinomaPreprint
Sun, L., Liu, Y., Zhou, H., Zhang, M., Cao, X., & Zhang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2349164/v1 · Cited by 2 · see citing works
Therapeutic Engineering and Drug Loading of MSC-Exosomes for Oncological Applications
Memur, A., & Baydin, P. O. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00449-2 · Cited by 1 · see citing works
Characterization of CSF2A fusion gene and its effect on Epstein–Barr virus–positive tumor cells
Sun, Y., Long, J., Yin, Y., Li, H., Jiang, E., Zeng, C., & Zhu, W. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25240 · Cited by 1 · see citing works
Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis
Cao, H., Cui, L., Ma, W., Zhu, L., Wang, K., Ni, Y., Wang, Y., & Du, J. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0475-y · Cited by 1 · see citing works
Polyethyleneimine based non-viral vectors for p53 Gene delivery in Cancer cells
Mali, A. (2017)
Target therapeutic exploitation of engineered exosome-mediated delivery of ncRNAs in cancer
Chaharlang, F., Mahdipour, N., Rami, S. A., Angouti, P., Ahmadi, A., & Khalaj‐Kondori, M. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01059-y
Genetic Medicine Approaches for Tumor Suppressor Loss: Therapeutic Replacement with Self-Amplifying RNA
Mutha, D., Vedula, C. P., Bhagavatula, S., Grinstaff, M. W., Wong, W. W., Lu, D., Ganem, N. J., & Flynn, R. L. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04174-5
BindingDB Entry 50022106: Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives.
BindingDB (2025) · UC San Diego · doi:10.7270/q29028gr

Authors: Nastiuk, K. L., & Krolewski, J. J.
Affiliations: Roswell Park Comprehensive Cancer Center (US)
Corresponding author: Krolewski, John J.
ORCID: Nastiuk, Kent L.
Krolewski, John J.
Venue: Advanced Drug Delivery Reviews
Publisher: Elsevier BV
Published: 2016-03
Volume: 98
Pages: 35-40
ISSN: 0169-409X (ISSN-L)
DOI: 10.1016/j.addr.2015.12.005
PMC: PMC4957561
OpenAlex: W2210056821
Cited by: 85
References: 99
Citations by year: 2026: 6 · 2025: 10 · 2024: 5 · 2023: 8 · 2022: 10 · 2021: 8 · 2020: 7 · 2019: 8 · 2018: 8 · 2017: 12 · 2016: 3
FWCI: 0.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advanced Drug Delivery Reviews (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA151753)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
Keywords: combination gene therapy, cancer gene therapy, metastatic cancer, treatment resistance, solid tumors, multidrug chemotherapy, targeted therapy, hormone therapy, drug delivery
MeSH terms: Animals, Antineoplastic Agents, Combined Modality Therapy, Humans, Neoplasms, Genetic Therapy, Apoptosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Opportunities and challenges in combination gene cancer therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks